Skip Navigation Links

Use of Internet Explorer for eRA Modules to be Phased Out by July 19, 2021

eRA is phasing out the use of the Internet Explorer browser for eRA modules effective July 19, 2021. For tips and tricks on troubleshooting browser configuration issues, please go here: Tips & Tricks for Fixing Browser Configuration Issues When Using eRA Modules.

Project Information

Previous Project 9356 of 1,242,751 Next

COMBINATION ANTI-AMYLOID THERAPY FOR PRECLINICAL ALZHEIMER'S DISEASE

Agency:
NIA

HHS/NIH/National Institute on Aging (NIA)

Project Number:
1R01AG061848-01
Contact PI / Project Leader:
AISEN, PAUL S.
Awardee Organization:
UNIVERSITY OF SOUTHERN CALIFORNIA

Description

Abstract Text:
PROJECT SUMMARY This is a multi-PI application for an R01 award under PAR-18-513. The proposed project titled “Combination Anti-Amyloid Therapy in Preclinical Alzheimer's Disease” is a multicenter randomized placebo-controlled two arm clinical trial of a combination anti-amyloid therapy: an anti-fibrillar amyloid antibody for the initial 18 months combined with BACE inhibition therapy for 4 years, in preclinical AD, defined as asymptomatic individuals with elevated brain amyloid as determined by florbetapir PET scanning. The primary outcome will be a cognitive composite (a modified version of the Preclinical Alzheimer's Cognitive Composite, PACC5), with functional and clinical assessments along with volumetric MR and tau PET as secondary outcomes (and, in a subset, CSF biomarkers). The specific Aims of the proposed study are; 1. to evaluate the impact of a combination anti-amyloid regimen on fibrillar amyloid in brain as indicated by amyloid PET SUVr, 2. to evaluate the efficacy and safety of a combination anti-amyloid regimen in individuals with preclinical AD, and 3. to evaluate the impact of the combination anti-amyloid regimen on AD biomarkers. Drs. Sperling and Aisen will share responsibility for scientific oversight of the clinical design and execution of the study and Imaging oversight will be provided by Dr. Johnson. The ACTC will provide the administrative and operational support, data capture and data management, clinical monitoring and site management, safety oversight, biostatistical support, and biomarker sample processing storage and support. Final selection of therapeutic agents for this trial will be made by a compound selection committee composed of field experts. Committee membership will include external experts in AD drug development and AD neurobiology, appointed in concert with NIA. The study team will work collaboratively with the pharmaceutical company researchers who have clinical experience with these therapeutics in development. This will be the first study of its kind: a potentially synergistic combination approach to dramatically reducing amyloid from asymptomatic individuals on the AD spectrum. Combination therapy trials are increasingly proposed by investigators and regulators to improve the likelihood of success in trials aiming for disease-modification. This approach could ultimately prevent the onset of AD symptoms
Project Terms:
Activities of Daily Living; Address; Alzheimer's Disease; Amyloid; Amyloid beta-Protein; amyloid peptide; Antibodies; arm; Atrophic; Award; beta secretase; beta-site APP cleaving enzyme 1; Binding; Biological Markers; Biometry; Blood; Brain; Cerebrospinal Fluid; Clinic; Clinical; Clinical assessments; clinical development; Clinical Trials; Cognition; Cognitive; cognitive function; Collaborations; Combined Modality Therapy; Committee Membership; computerized; cooperative study; Data; data management; design; Development; Disease; Disease Progression; drug development; effective therapy; Enrollment; Epidemic; exosome; experience; Futility; Generations; high risk; Hippocampus (Brain); Image; Impaired cognition; improved; indexing; Individual; inhibitor/antagonist; instrument; Intervention; Magnetic Resonance; Magnetic Resonance Imaging; Measures; Modification; Monitor; Neocortex; Nerve Degeneration; Neurobiology; neurofilament protein L; Neurons; Oral; Participant; Pathologic; Pathology; Pathway interactions; Patient Self-Report; Pharmaceutical Preparations; Pharmacologic Substance; Placebos; Plasma; Positron-Emission Tomography; pre-clinical; pre-clinical therapy; prevent; Prevention; primary outcome; Randomized; Randomized Controlled Trials; Regimen; Research Personnel; Safety; Sampling; secondary outcome; Senile Plaques; Site; success; Symptoms; tau Proteins; tau-1; Testing; Therapeutic; Therapeutic Agents; Therapeutic Human Experimentation; Therapeutic Trials; Therapy trial; tool; Treatment Protocols; uptake; Ventricular; Work

Details

Contact PI / Project Leader Information:
Name:  AISEN, PAUL S.
Other PI Information:
JOHNSON, KEITH A.; SPERLING, REISA A.
Awardee Organization:
Name:  UNIVERSITY OF SOUTHERN CALIFORNIA
City:  LOS ANGELES    
Country:  UNITED STATES
Congressional District:
State Code:  CA
District:  34
Other Information:
Fiscal Year: 2018
Award Notice Date: 15-Sep-2018
DUNS Number: 072933393
Project Start Date: 30-Sep-2018
Budget Start Date: 30-Sep-2018
CFDA Code: 866
Project End Date: 31-May-2023
Budget End Date: 31-May-2019
Agency: ?

Agency: The entity responsible for the administering of a research grant, project, or contract. This may represent a federal department, agency, or sub-agency (institute or center). Details on agencies in Federal RePORTER can be found in the FAQ page.

HHS/NIH/National Institute on Aging (NIA)
Project Funding Information for 2018:
Year Agency

Agency: The entity responsible for the administering of a research grant, project, or contract. This may represent a federal department, agency, or sub-agency (institute or center). Details on agencies in Federal RePORTER can be found in the FAQ page.

FY Total Cost
2018 NIA

HHS/NIH/National Institute on Aging (NIA)

$9,021,816

Results

i

It is important to recognize, and consider in any interpretation of Federal RePORTER data, that the publication and patent information cannot be associated with any particular year of a research project. The lag between research being conducted and the availability of its results in a publication or patent award varies substantially. For that reason, it's difficult, if not impossible, to associate a publication or patent with any specific year of the project. Likewise, it is not possible to associate a publication or patent with any particular supplement to a research project or a particular subproject of a multi-project grant.

ABOUT FEDERAL REPORTER RESULTS

Publications: i

Click on the column header to sort the results

PubMed = PubMed PubMed Central = PubMed Central Google Scholar = Google Scholar

Patents: i

Click on the column header to sort the results

Similar Projects

Download Adobe Acrobat Reader:Adobe Acrobat VERSION: 3.41.0 Release Notes
Back to Top